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Abstract
Background: Gorham-Stout disease (OMIM 123880) and generalized lymphatic anomaly are two rare disorders of
lymphendothelial growth in which thoracic involvement with chylothorax is a feared complication. Currently it is
believed that both disorders are prenatal malformations that progress slowly after birth. Several pharmaceuticals
with antiproliferative properties, including interferon-α-2b, rapamycin and propranolol, have however been shown
to affect the disease course in some patients. Deeper knowledge of the growth characteristics of these
malformations are therefore needed to guide the clinical approach.
Methods: Lymphatic vessels in lung and pleural tissue from both children and adult patients with generalized
lymphatic anomaly or Gorham-Stout disease were studied using an immunohistochemical approach, targeting
lymphendothelial markers (D2-40/Prox-1) and a proliferation marker (Ki-67).
Results: We found significant proliferation and growth in these lesions in pediatric patients but not in adults.
Furthermore, the data may suggest that the disease process is at least partly reversible.
Conclusions: These malformations of the lymphatic system proliferate at a significant rate long after birth, which
could suggest that the clinical approach for children should be different from adults.
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Background
Lymphatic malformations (LM) constitute a broad group of
disorders, ranging from single lesions to wide spread disease
[1]. Systemic conditions include generalized lymphatic
anomaly (GLA), Gorham-Stout disease (GSD; OMIM
123880) and Kaposiform lymphangiomatosis (KLA), all con-
sidered to be very rare entities [2–4]. The classification of
these conditions is challenging, the literature uses descrip-
tive and inconsistent terminology, and few papers describe
more than a small number of patients. GSD is an LM
characterized by progressive osteolysis, whereas the related
condition, GLA, also may have skeletal involvement, how-
ever without progressive loss of cortical bone [5]. Both con-
ditions are thought to be congenital and the general belief is
that the lymphatic endothelial cells (LECs) of these LMs do
not dived rapidly after birth, although their clinical course is
progressive in nature [6]. Symptoms may occur from in-
fancy into adulthood. In both GLA and GSD a feared com-
plication of intrathoracic involvement is effusion of chyle
into the pleural cavity (chylothorax). This condition is often
difficult to manage [7] and is associated with high morbidity
and mortality. In the literature there are many suggested
therapies ranging from drainage, pleurodesis and radiother-
apy [6] to pharmaceutical drugs such as interferon-α-2b
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[8], propranolol [9], rapamycin [2], low-molecular weight
heparin [7] and anti-VEGF antibodies [10]. Even though
the endothelial cells of these lesions are thought to have a
low rate of division, many of the pharmaceuticals used (and
reported to be at least partly efficient) strongly affect cell
proliferation. We therefore set out to study whether LECs
in patients with either GLA or GSD really were semi-
quiescent and if not, whether there was an age difference.
We also studied biopsy material before and after treatment
in a young girl with GLA to determine whether these pro-
cesses are potentially reversible.
Methods
Study cohort
There are no large collections of fixed tissue from patients
with GSD or GLA, which makes statistical analysis of im-
munohistochemical results challenging. We set out to cre-
ate a biobank of formalin-fixed material in these
conditions, including tissue from the skeleton, bone mar-
row, spleen and soft tissues (e.g., skin, fat and connective
tissue). Material was retrieved from pathology laboratories
in Sweden, Spain, Italy and the biobank NDRI (National
Disease Research Interchange) in Philadelphia, USA. The
tissue origin and patient data are presented in Table 1. In
the collection there is also material from peripheral parts
of lungs or pleurae from 8 patients, including 5 children
(6 months-16 years of age) and 3 adults (>23 years of age),
all of whom had developed chylothorax. Clinical details
are listed in Table 2. In total, material from 23 GSD and
GLA patients was collected and is now available for col-
laborative studies. As controls for this study, tissue blocks
of normal lung and pleura were obtained from the Dept.
of Pathology (Lund, Sweden; 2 pediatric and 3 adult pa-
tients), Sahlgrenska University Hospital (Gothenburg,
Sweden; 2 adult patients), and the University Hospital of
Umeå (Umeå, Sweden; 1 pediatric patient). Two pediatric
controls died from complications not related to the lungs
(acute cardiac arrest) and one was investigated for isolated
pericardial effusion. Four adult patients succumbed from
causes not related to the pulmonary system and their
lungs were taken for donation, whereas one died from
pneumothorax.
Immunohistochemistry (IHC)
Tissue samples were fixed in 10 % formalin, dehydrated
and embedded in paraffin. In total, 46 tissue blocks were in-
cluded in the study; 32 tissue blocks from patients with
GSD or GLA and 14 tissue blocks from controls. Paraffin
sections of three-micron-thickness were heated to 60 °C for
20 min and then subjected to simultaneous dewaxing and
heat-induced antigen retrieval in high pH (EnVision FLEX
Target Retrieval Solution, K8010, Dako, Glostrup,
Denmark) using a Dako Pre-Treatment Module. To avoid
staining variations between slides, all immunohistochemical
stainings were carried out in an automated slide staining
robot (Autostainer Plus, DakoCytomation, Glostrup,
Denmark) and each IHC run contained sections from both
study groups. Adjacent tissue sections were first treated
with 0.3 % hydrogen peroxide for 10 min to block endogen-
ous peroxidase activity and then incubated for 1 h with
antibodies directed against Prox1 (1:600, rabbit polyclonal,
ab38692, Abcam, Cambridge, UK) or Ki-67 (1:150, mouse
monoclonal, M7240, Dako, Glostrup, Denmark). Next,
sections were treated with Polymer/HRP-linked sec-
ondary antibodies (K8010, Dako) for 30 min and immu-
noreactivity was visualized with 3,3′-diaminobenzidine
(DAB) chromogen (brown-colored product, K8010,
Dako). An additional blocking step with Denaturating
Solution kit (DNS001L, Biocare Medical, Concord, CA,
USA) for 5 min was performed to prevent additional
binding to the first primary antibody [11, 12]. Sections
were then incubated with mouse anti-human D2-40
antibodies (1:300, CM266, Biocare Medical) and immu-
noreactivity was visualized with Polymer/HRP-linked
secondary antibodies (K8010, Dako) and Vina Green
Chromogen kit (green-colored reaction, BRR807AS,
Table 1 Collection of non-pulmonary specimens from patients
with Gorham-Stout disease or generalized lymphatic anomaly
Subject Original diagnosis











3 GSD Leg F 56
4 GSD Bone marrow F 34
5 GSD Frontal bone,
spleen
F 5
6 GSD Cervical bone M 5





9 GSD Skin F 8
10 GSD Soft tissue unknown unknown
11 GSD Skin, soft tissue M unknown
12 GSD Skin M 15
13 GSD Bone F 14
14 GSD Bone, soft tissue F 10
15 GSD Skin M 4
16 GLA Bone marrow F 4
17 GLA Bone, crista M 3
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Biocare Medical). Finally, sections were counterstained
with Mayer’s hematoxylin, air-dried and mounted with
Pertex.
Quantitative assessments of lymphatic vessels
Whole sections were digitalized using a slide-scanning
robot (ScanScope Slide Scanner, Aperio Technologies,
Vista, CA, USA). Morphometric and immunohistochem-
ical measurements were performed on the generated
digital images using Aperio ImageScope Image Analysis
Software (V.10.0, Aperio Technologies) [11, 12].
Total D2-40 immunoreactivity in whole sections was
assessed by manually delineating the perimeter of the
whole tissue and calculating the percentage of the total
tissue area occupied by D2-40-staining (i.e. the number of
green-colored positive pixels related to the total number of
tissue pixels) using Aperio Positive Pixel Count Algorithm
v.9 (ImageScope, Aperio Technologies) (see Additional
file 1). Pixels corresponding to Prox1 immunoreactivity
(brown color) were automatically excluded in the analysis.
The numbers of Prox1+/D2-40+ lymphatic vessels in
each section were counted and data were normalized to
the tissue area, which was assessed by counting the
number of pixels corresponding to the tissue (i.e., ex-
cluding air/luminal spaces). In lung sections, all bronchi-
oles (absence of cartilage and diameter <2 mm) and
bronchiole-associated arteries, as well as multiple soli-
tary blood vessels (at a distance from bronchioles) and
large areas of alveolar tissue were analyzed on each sec-
tion. In pleural sections, four randomly selected areas
(about 3.6 mm2 each) were analyzed on each section. In
the same regions the numbers of lymphatic vessels
showing at least one Ki-67+ lymphatic endothelial cell
nucleus were counted to reveal the percentage of lymph-
atic vessels in active proliferation.
Statistics
Statistical analysis was performed using GraphPad Prism
V.6.0 (GraphPad software, San Diego, CA, USA). Mann-
Whitney rank sum nonparametric test was used for
comparison between the two study groups. Values are
given as median (range), unless otherwise stated.
Results
Lymphatic volume
First, we set out to study the area of tissue that was occu-
pied by lymphatic vessels using the LEC marker D2-40.
The area was defined as the D2-40 positive area/total tissue
area (excluding air and luminal spaces) (Fig. 1a, Additional
file 1). In control samples from both lung tissue and pleurae
the average area covered by lymphatic vessels was 0.6 %
(Fig. 1a). In patients with GLA or GSD this area was con-
siderably larger, with an average of 3.5 %, p = 0.0002
(Fig. 1a). Further, the number of Prox1+/D2-40+ vessels per
mm2 tissue also was clearly increased in patients compared
to controls (38 versus 12; p = 0.0047) (Fig. 1b). Interestingly,
there was a clear trend towards fewer lymphatic vessels per
mm2 in adult tissue than in tissue from children. The
lymphatic vessel perimeter was often larger in patients
compared to controls. The typical immunohistochemical
appearance of the lymphatic vessels is shown in Fig. 1c-f.
Proliferation rate
Proliferation of LECs was assessed using double staining
for D2-40 and the proliferation marker Ki-67. In the
control group, except for one sample analyzed, there
was no significant proliferation at all. In GLA/GSD pa-
tients, however, 12.5 % of the lymphatic vessels on aver-
age contained proliferating cells (Fig. 2). There was a
significant difference (p = 0.036) between samples from
adult and pediatric patients, where the adult patients on
average showed proliferating cells in 5 % of the lymph-
atic vessels whereas the pediatric population on average
had 17.5 %.
Effect of antiproliferative treatment
As the aberrant lymphatics in GSD/GLA are thought to
be malformations with a low rate of proliferation, we stud-
ied this feature in lung/pleural tissue before and after
treatment in a young girl suffering from GLA, whose clin-
ical history has been published (Brodszki et al., 2011, case
2 [7]). In short, a female patient was diagnosed at four
Table 2 Collection of lung and pleural specimens from patients
with Gorham-Stout disease or generalized lymphatic anomaly,
and controls
Subject GSD a/GLA b/Control Gender (M/F) Age (yrs.) c
1 GLA M 3
2 GLA F 54
3 GSD F Infant
4 GLA F 4
5 GLA M 3
6 GLA F 35
7 GLA F 57
8 GSD M 0.5
9 Control M 0.5
10 Control M 23
11 Control M 25
12 Control M 36
13 Control F 8
14 Control M 16
15 Control M 65
16 Control F 63
a Gorham-Stout disease
b Generalized lymphatic anomaly
c Age at diagnosis
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years of age with bilateral chylothorax after persistent back
pain. The initial CT-scan revealed several fractured ribs,
sternum fracture and diffuse osteolytic changes in the
humerus, femur, pelvis, sacrum and multiple vertebrae.
Cystic changes were noted in the spleen as well. The diag-
nosis of GSD was made on the basis of the clinical symp-
toms, radiological findings and histology. In retrospect,
the correct diagnosis was GLA following the criteria by
Lala et al. [5] as the bone lesions were not progressively
osteolytic. The patient was treated with radiotherapy,
octreotide, interferon-α − 2b/pegylated interferon and
tafoxiparin as described in the initial publication [7]. Her
chylothorax resolved permanently but the osteolytic
changes never remitted and she became paraplegic
3.5 years later after collapse of the thoracic spine (at
Th10). The treatment was broadened to include daily
rapamycin, propranolol and triweekly intravenous infusion
of pamidronate. She succumbed to sepsis, which was
deemed unrelated to the GLA. At a restricted necropsy,
tissue from the lung/pleurae was harvested and analyzed
Fig. 1 Lymphatic volume in patients with Gorham-Stout disease (GSD) and generalized lymphatic anomaly (GLA). a Quantification of the total tissue
immunoreactivity for D2-40+ lymphatic endothelial cells in lung and pleural tissue. b Numbers of Prox1+/D2-40+ lymphatic vessels normalized to the lung/
pleural tissue area. Statistical analysis was performed using Mann-Whitney rank sum test. Horizontal lines indicate median values. Open symbols: children
(6 months-16 years of age). Black symbols: adults (>23 years of age). c-f Immunohistochemical staining for Prox1 (brown-colored nuclei, see inlet of Fig. 1c)
and D2-40 (in green) in controls (left panel) and patients with GSD/GLA (right panel). Lymphatics with long vessel perimeter are exemplified in (d) and (f).
Representative photomicrographs of histological sections of lung tissue (in c-d) and pleural tissue (in e-f). Cell nuclei were counterstained with Mayer’s
hematoxylin (blue). Scale bars: (c-f) 50 μm
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for presence of lymphatic malformations. This was then
compared to the tissue submitted at the time of diagnosis,
which showed that on average 4 % was made up of lymph-
atic (D2-40+) cells, whereas only 0.5 % of the tissue was
D2-40+ at the time of death (Fig. 3a). Further, the number
of lymphatic vessels per mm2 tissue, decreased from 40 to
5 between diagnosis and death (Fig. 3b) and the percent-
age of actively proliferating lymphatic vessels went from
11 % to null (Fig. 3c). These data indicate thus that al-
though the number of vessels and their proliferative
activity were elevated at diagnosis, both parameters were
reversible at this stage.
Discussion
In the latest classification from the International Society
for the Study of Vascular Anomalies (ISSVA) [1], GLA
and GSD are classified as two different disorders, though
they share many features. Furthermore, the related and
seemingly even more aggressive LM, KLA, may share
features of these two other conditions [3, 4]. The
Fig. 2 Lymphatic proliferation rate in patients with Gorham-Stout disease (GSD) and generalized lymphatic anomaly (GLA). a Quantification of
lymphatic vessels with actively proliferating lymphatic endothelial cells in lung and pleural tissue. Statistical analysis was performed using Mann-
Whitney rank sum test. Horizontal lines indicate median value. Open symbols: children (6 months-16 years of age). Black symbols: adults (>23 years
of age). b-e Immunohistochemical staining for Ki67 (brown-colored nuclei) and D2-40 (in green) in patients with GSD/GLA. Representative
photomicrographs of histological sections of lung tissue (b-c) and pleural tissue (d-e). Cell nuclei were counterstained with Mayer’s
hematoxylin (blue). Scale bars: (b-e) 50 μm
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diagnostic differences between GLA and GSD include
the ‘most common skeletal location’ and ‘radiographic
appearance of the skeletal lesions’ [5]. The skeletal dis-
ease course appears more aggressive in GSD, while the
diagnosis of GLA may allow for await-and-see approach
rather than intervention [13]. However, pleuropulmon-
ary involvement, when present, seems to be indistin-
guishable in the two conditions, which offered us a
rationale for combining the material from GLA and
GSD patients to augment the study cohort. None of the
studied patients presented with foci of spindled LECs
and KLA was therefore ruled out [4]. There is no stan-
dardized treatment for these often-fatal conditions, and
several approaches have been used over the years. These
include pharmacological substances such as interferon-
α-2b [8], propranolol [9, 14], rapamycin [2], and bevaci-
zumab [10], but also local radiotherapy [15], sclerosing
therapy [16] and ligation of the thoracic duct (in chy-
lothorax) [17]. Recently, a combination of sunitinib and
taxol was also suggested [13]. Despite the fact that most
of these therapies exert their potentially beneficial effects
as anti-proliferation agents, the lymphatic lesions in
GLA and GSD are considered to be slowly dividing mal-
formations rather than highly proliferating tumor-like
structures. To study whether this is true in all age
groups and whether the process is reversible we first col-
lected specimens from different organs in patients of
various ages, in order to create a tissue biobank from
these rare patients for use by the scientific community.
At present, we have formalin-fixed paraffin-embedded
tissue from 23 patients as described in Tables 1 and 2. In
our biobank we then identified material from eight pa-
tients with pleuropulmonary involvement and compared
them to pulmonologically healthy age-matched individ-
uals. The total tissue area covered by lymphatic vessels
was increased four-fold over normal tissue (3.5 % com-
pared to 0.8 %), a relation apparently not previously
quantified. This was accompanied by a significantly in-
creased number of lymphatic vessels per mm2 of tissue
in the patients, indicating the strong impact of these dis-
orders on lymphangiogenesis. These findings, together
with the observation that the lymphatic vessel perimeter
appeared to be larger in patients, may indicate that the
increase in total volume is not only caused by the LMs
containing more vascular structures but also wider ves-
sels. Using double staining for D2-40 and Ki-67, we
could show that the number of actively proliferating
lymphatic vessels in tissue from pediatric patients was
clearly higher than in the adult population (18 % vs 5 %),
whereas there were virtually no Ki-67-positive LECs in
the controls. This indicates that there is an intensive ex-
pansion of the pleuro-pulmonary LMs during the first
decades of life. Drugs affecting this process are thus
more likely to be effective at a younger age.
The factors driving the proliferation of lymphatic
vessels in patients with GSD or GLA are not known
but may include known lymphangiogenic cytokines
such as vascular endothelial growth factor (VEGF)-A,
VEGF-C, VEGF-D and platelet-derived growth factor
(PDGF)-BB [18]. In line with this we previously re-
ported increased serum levels of VEGF-A in two
pediatric patients with GLA and increased levels of
VEGF-C in one patient [7]. Another study showed that
lymphatic vessels in a GSD patient expressed both
VEGFR3 and PDGFR-β, in addition to receptors for
VEGF-C/D and PDGF-BB [19]. An interesting animal
model of the related human disorder pulmonary lym-
phangiectasia [20], using perinatal overexpression of
VEGF-C, implies the involvement of both VEGFR2
and VEGFR3 in aberrant pulmonary lympangiogenesis.
Fig. 3 Antiproliferative treatment effects on lung and pleural lymphatic vessels in a 4-year-old with generalized lymphatic anomaly. a
Quantification of the total tissue immunoreactivity for D2-40+ lymphatic endothelial cells before and after antiproliferative treatment. b
Numbers of Prox1+D2-40+ lymphatic vessels normalized to the tissue area. c Quantification of lymphatic vessels with actively proliferating
lymphatic endothelial cells
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Whether this model can be used to mimic the patho-
genesis of GLA/GSD is not known and future studies
need to define the mechanisms causing the lymphatic
proliferation in patients with these conditions.
In a deceased patient, we could show that the LM-
forming process was reversible, as the infiltrating LMs at
diagnosis were largely absent at the time of death.
Whether this was caused by the GLA targeted treatment
or non-related factors associated with the death of the
patient is however impossible to determine postmortem
in a single case.
In conclusion, we stress the possible importance of an
early diagnosis and treatment, as opposed to the ‘await
and see’ philosophy suggested by Rössler et al. [13], since
waiting may render the disease less treatable. Indeed, in
our clinical experience, many of the pharmacological ap-
proaches suggested in the literature have been largely in-
effective in adult patients with chylothorax. Our data
also may suggest that children and adults with GLA/
GSD and chylothorax should be treated differently. The
number of patients in this study is however limited and
would ideally be expanded to further strengthen this
conclusion.
Conclusions
In this paper we describe the creation of a tissue biobank
with material from in total 23 patients with GLA or
GSD, which is open for collaborative ventures to study
these rare entities. We focused on LMs in the pleuropul-
monary system of GLA and GSD patients and show that
there is significant LM proliferation during childhood,
but not in adults, which may have implications for the
choice of therapy.
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